Nyrada (ASX:NYR) has announced positive results from a preclinical rat study evaluating the efficacy of its lead drug candidate, NYR-BI03, in coronary heart disease.
The company said the study demonstrated NYR-BI03's strong efficacy in limiting cardiovascular damage following acute myocardial ischemic-reperfusion injury.
Ischemic-reperfusion injury is a leading cause of tissue damage following restoring blood flow to the heart post-injury.
Nyrada said NYR-BI03 demonstrated strong and statistically significant cardioprotection following a myocardial infarction by reducing cardiac tissue damage by 86 per cent.
NYR-BI03 is being developed as a first-in-class neuroprotection treatment for both stroke and traumatic brain injury.
In February 2024, Nyrada reported preclinical stroke study results showing NYR-BI03 provided a statistically significant level of neuroprotection, rescuing 42 per cent of brain injury in the penumbra region in treated animals.
Nyrada said it commissioned a rat study in a model of acute myocardial ischemia-reperfusion injury to assess the cardioprotective efficacy of NYR-BI03.
"The results demonstrated strong cardioprotection that was superior to Captopril, an FDA-approved ACE inhibitor commonly administered following ischemic events and used in this study as a positive control. This positions NYR-BI03 as a novel cardioprotective treatment following myocardial infarction," said Nyrada.
Nyrada CEO James Bonnar said, “This is an exciting development for Nyrada, presenting additional therapeutic and commercial options for our lead drug candidate NYR-BI03.
“The cardiovascular study results announced today leverages Nyrada’s TRPC knowledge and expertise. The preclinical Good Laboratory Practice (GLP) package being assembled for our brain injury program can also be utilised to support clinical development in this indication.
“Nyrada continues to pioneer the development of TRPC channel blocking therapies.”
NYR-BI03 is undergoing GLP safety and tolerability studies ahead of a first-in-human Phase I clinical trial expected to commence in the quarter ending December 2024.
